梅州医院做人流手术多少钱梅州大腿吸脂一般多少钱,梅州小阴唇肥大手术多少钱,梅州双下巴整形,梅州做人流什么医院较好,梅州妇科医院广空好,梅州人工打胎注意,梅州轻微宫颈糜烂

HONG KONG, March 18 (Xinhua) -- After over a year's efforts, scientists from Shanghai and Hong Kong announced on Friday that they have completed the whole genomic sequencing work of Isaria cicada, a rare herb highly valued in traditional Chinese medicine, which will help facilitate its further development in medical and nutrition fields.It is the first time that the whole genomic sequence of Isaria cicada has been released, said the scientists from Shanghai Institute of Bio-Asia Life Science and the Hong Kong University of Science and Technology (HKUST), who participated in the research.The result was announced at the International Biomedical Scientists and Biotechnology Forum 2011 held in the day at the Hong Kong Science Park.According to the result, the genomic size of Isaria cicada, a medicine traditionally used to treat children's diseases, is about one eightieth of human genome, containing about 16,000 genes.The tests that had been done proved that Isaria cicada, with many high-quality genes not recognized or used by human beings yet, has been deeply involved in important life processes like metabolism, providing new ways for further development of Isaria cicad in bio-medical area, said a scientist from HKUST.The genome map will also help accelerate the artificial cultivation of Isaria cicada, enhancing its medicine and nutrition value and making it available in a larger market, according to the scientist.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

SAN FRANCISCO, March 22 (Xinhua) -- Apple Inc. on Tuesday announced that iPad 2, the second-generation of its popular tablet computer, will be available in China's Hong Kong, Korea, Singapore and additional countries and regions in April.The company also confirmed that iPad 2 will go on sale in 25 countries on March 25 in addition to the United States, where the device first hit market on March 11 and has seen strong demand."While competitors are still struggling to catch up with our first iPad, we've changed the game again with iPad 2," Steve Jobs, Apple's chief executive officer, said in a statement."We're experiencing amazing demand for iPad 2 in the U.S., and customers around the world have told us they can't wait to get their hands on it. We appreciate everyone's patience and we are working hard to build enough iPads for everyone," he noted.Apple had planned to released iPad 2 in Japan on March 25, but delayed the launch in the aftermath of the catastrophic March 11 earthquake and ensuing tsunami in the country.The 25 countries where iPad 2 will go on sale on March 25 include Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland and Britain.

WELLINGTON, May 22 (Xinhua) -- One in every eight women giving birth in a New Zealand hospital last year was Asian, local media reported Sunday.In the country's most populous city, Auckland, 5,149 Asian women gave birth, more than double the number of 15 years ago, the New Zealand Herald reported.Last year was the first year in the city when more Asian women gave birth than indigenous Maori women, who registered 5,015 births.Citing figures from the government statistics agency, Statistics New Zealand, the report said the majority of women nationwide who gave birth last year were still of European descent, accounting for 43,965 of last year's 63,897 births.But more women of other ethnic backgrounds were also becoming mothers, including those from the Middle East, Latin America and Africa.Auckland University head of obstetrics and gynaecology, Professor Lesley McCowan, said the increase reflected New Zealand is an increasingly multicultural society.

BEIJING, April 19 (Xinhuanet) -- The case in the Hollywood blockbuster "The Social Network" continues in real life.Twins Cameron and Tyler Winklevoss on Monday filed another appeal against their Harvard classmate and Facebook founder Mark Zuckerberg.The Winklevosses claim that the case needs to be reviewed by a special 11-judge panel in the latest appeal, after a three-judge panel of the 9th U.S. Circuit Court of Appeals ruled against the brothers last week.The twins initially claimed that Zuckerberg had stolen their idea for the website but agreed to drop their lawsuit in 2008 in exchange for 20 million dollars in cash and stock in the company.But later they discovered the stock was worth less than claimed at the time and sought to have the deal voided, the brothers said.